No Shame

Well it looks like Livongo isn’t the only diabetes company using the current crisis to inflate the value of their shares, check this out;

“Nemaura Medical (NSDQ:NMRD) announced today that it is planning to immediately repurpose its SugarBeat continuous glucose monitor (CGM) as a continuous temperature monitor (CTM) to help diagnose fevers in potential cases of COVID-19.”

You can read the entire story at

Before we go on we must admit we are disappointed that the normally well-respected Drug Delivery Business web . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.